ATE231504T1 - Pyrazolderivate und sie enthaltende cox- inhibitoren - Google Patents

Pyrazolderivate und sie enthaltende cox- inhibitoren

Info

Publication number
ATE231504T1
ATE231504T1 AT98912761T AT98912761T ATE231504T1 AT E231504 T1 ATE231504 T1 AT E231504T1 AT 98912761 T AT98912761 T AT 98912761T AT 98912761 T AT98912761 T AT 98912761T AT E231504 T1 ATE231504 T1 AT E231504T1
Authority
AT
Austria
Prior art keywords
compounds
cox
lower alkyl
halogeno
disturbances
Prior art date
Application number
AT98912761T
Other languages
English (en)
Inventor
Tomoji Aotsuka
Nagatoshi Wagatsuma
Hideo Kato
Naoki Ashizawa
Original Assignee
Grelan Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grelan Pharmaceutical Co filed Critical Grelan Pharmaceutical Co
Application granted granted Critical
Publication of ATE231504T1 publication Critical patent/ATE231504T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98912761T 1997-04-11 1998-04-10 Pyrazolderivate und sie enthaltende cox- inhibitoren ATE231504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10829997 1997-04-11
PCT/JP1998/001664 WO1998046594A1 (fr) 1997-04-11 1998-04-10 Derives de pyrazole et inhibiteurs de cox les renfermant

Publications (1)

Publication Number Publication Date
ATE231504T1 true ATE231504T1 (de) 2003-02-15

Family

ID=14481176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912761T ATE231504T1 (de) 1997-04-11 1998-04-10 Pyrazolderivate und sie enthaltende cox- inhibitoren

Country Status (6)

Country Link
US (1) US6136831A (de)
EP (1) EP1006114B1 (de)
JP (1) JP4357004B2 (de)
AT (1) ATE231504T1 (de)
DE (1) DE69810938T2 (de)
WO (1) WO1998046594A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CA2381895A1 (en) * 1999-08-27 2001-03-08 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
FR2831537B1 (fr) * 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
EP1442028A4 (de) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co Substituierte säurederivate, die sich als antidiabetika und mittel gegen obesitas eignen, und verfahren
US6861533B2 (en) 2001-11-23 2005-03-01 Irm Llc Solution phase sythesis of arylbenzoxazoles
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
EP1539679A4 (de) 2002-06-28 2007-07-04 Nitromed Inc Oxim- und/oder hydrazonhaltige, nitrosierte und/oder nitrosylierte cyclooxigenase-2-selektive inhibitoren, zusammensetzungen und anwendungsverfahren
JP4468810B2 (ja) 2002-07-24 2010-05-26 キューエルティー インコーポレーティッド ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
EP1534305B9 (de) 2003-05-07 2007-03-07 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
EP2266584B1 (de) 2003-05-07 2012-09-05 Osteologix A/S Strontium-Vitamin D-Zusammensetzung zur Prophylaxe/Behandlung von Knorpel- und Knochenzuständen
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
EP1708718A1 (de) 2004-01-22 2006-10-11 Pfizer Limited Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität
JP2007534740A (ja) * 2004-04-28 2007-11-29 ファイザー・インク バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
WO2008047694A1 (fr) * 2006-10-13 2008-04-24 Aska Pharmaceutical Co., Ltd. Procédé de fabrication d'un composé benzothiazole
EA017171B1 (ru) 2006-12-22 2012-10-30 Рекордати Айерленд Лимитед КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1269495A (en) * 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

Also Published As

Publication number Publication date
EP1006114B1 (de) 2003-01-22
EP1006114A1 (de) 2000-06-07
WO1998046594A1 (fr) 1998-10-22
DE69810938D1 (de) 2003-02-27
DE69810938T2 (de) 2003-11-06
US6136831A (en) 2000-10-24
EP1006114A4 (de) 2000-06-07
JP4357004B2 (ja) 2009-11-04

Similar Documents

Publication Publication Date Title
ATE231504T1 (de) Pyrazolderivate und sie enthaltende cox- inhibitoren
NO953305D0 (no) Antranilsyrederivat
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
ATE280164T1 (de) Benzothiadiazine als matrix metallproteinase inhibitoren
NO20015669D0 (no) Heterocykliske substituerte aminoazacykler nyttige som sentralnervesystemmidler
MX2007000016A (es) Derivados de pirazol.
DK0887344T3 (da) Quinoliner og quinazoliner, som er nyttige ved terapi
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
DK0425209T3 (da) Naphtyloxazolidon Derivater
DK0514277T3 (da) 3-aminopyradazinderivater med virkning på centralnervesystemet
TR200001950T2 (tr) İkameli 2-benzilamino-2-fenil-asetamid bileşikler.
DK0875506T3 (da) Quinolin- og quinazolin-forbindelser, som er anvendelige til behandling
ATE327979T1 (de) Pyrazolinon-derivate
FI914007A0 (fi) 4-substituerade dihydropyrido (4,3-d) pyrimidiner som smaertslindrande och lokala inflammationshaemmande medel vid vaord av hudsjukdomar.
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
WO1998051667A1 (fr) Derives d'indole et derives de mono- et diazaindole
MX9709955A (es) Derivados del acido 5-pirazolilbenzoico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties